CMC – Page 23 – Pharma.Tips

QbD elements missing during IND/NDA filing – CMC risk assessment and mitigation

Addressing Missing QbD Elements during IND/NDA Submissions: A Playbook for Pharma Professionals In today’s highly regulated pharmaceutical landscape, the seamless submission of Investigational New Drug (IND) and New Drug Application…

Bioavailability risk flagged during scale-up preparation – CMC risk assessment and mitigation

Mitigation Playbook for Bioavailability Risks During Scale-Up Preparation Bioavailability risks during scale-up preparation present significant challenges in the realm of pharmaceutical development. As teams transition from R&D to production, the…

Prototype not scalable during IND/NDA filing – preventing late-stage reformulation

Addressing Scalability Challenges During IND/NDA Filings to Prevent Late-Stage Reformulation As pharmaceutical professionals engaged in formulation and process development, encountering a prototype not scalable during IND/NDA filing stages is a…

Bioavailability risk flagged during regulatory review – regulatory expectations for formulation data

Managing Bioavailability Risks Identified During Regulatory Review: A Comprehensive Playbook In the pharmaceutical manufacturing landscape, the identification of bioavailability risks during regulatory review can pose significant challenges for formulation development…

Prototype not scalable during scale-up preparation – regulatory expectations for formulation data

Tackling Scalability Issues in Formulation Development: An Actionable Playbook In the realm of pharmaceutical manufacturing, the transition from prototype to scalable production can often present unforeseen challenges. A failure to…

Formulation fails stability targets during scale-up preparation – CMC risk assessment and mitigation

Mitigating Risks When Formulation Fails Stability Targets During Scale-Up Preparation In pharmaceutical development, the transition from small-scale formulation to large-scale production is fraught with risk. One of the most critical…

Dissolution variability unexplained during IND/NDA filing – CMC risk assessment and mitigation

Addressing Unexplained Dissolution Variability During IND/NDA Filing: A Comprehensive Playbook Dissolution variability during the Investigational New Drug (IND) and New Drug Application (NDA) filing can lead to significant delays, regulatory…

QbD elements missing during regulatory review – how to redesign formulation strategy

Identifying Missing QbD Elements During Regulatory Review and Redesigning Formulation Strategy In the pharmaceutical sector, the absence of Quality by Design (QbD) elements during regulatory reviews can lead to significant…

Excipient incompatibility identified late during scale-up preparation – how to redesign formulation strategy

Strategies for Addressing Late-Stage Excipient Incompatibility in Formulation Development During the critical phase of scale-up preparation, pharmaceutical development teams may encounter excipient incompatibility issues, which can severely impact timelines and…

Tech Transfer Failures? Documentation and Execution Solutions

Addressing Challenges in Tech Transfer Documentation and Execution In pharmaceutical manufacturing, tech transfer remains a critical process that underpins the successful scale-up of products from development to production. However, failures…

Process Not Scaling? Development and Control Strategy Solutions

Troubleshooting Process Development and Control Strategies for Successful Scaling In the complex landscape of pharmaceutical manufacturing, a common impediment faced during the scale-up phase is the failure to ensure that…

Formulation Instability Problems? Development Solutions for Robust Products

Addressing Formulation Instability: Expert Solutions for Robust Product Development Formulation instability can significantly hinder the development of pharmaceutical products, leading to unexpected failures during stability testing, altered bioavailability, or challenges…